使用生物药物和小分子抑制剂来管理上腺炎
Victoria Fang1, Radhika Gupta2, Robert G Micheletti3
1Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Dermatologic clinics
|March 1, 2025
概括
补腺炎 (HS) 的管理需要一种系统的方法. 本综述涵盖生物和小分子疗法,为治疗这种慢性炎症性皮肤疾病的临床医生提供基于证据的算法指南.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 补腺炎 (HS) 是一种慢性炎症性皮肤疾病,严重影响患者的生活质量.
- 目前FDA批准的治疗方法包括阿达利穆马布和塞库金努马布.
- 许多其他生物和小分子抑制剂被非标签使用或正在研究中.
研究的目的:
- 审查在HS管理中抗炎生物和小分子疗法的最新证据.
- 提供HS治疗的实用,算法方法,结合专家意见和临床经验.
主要方法:
- 对HS的生物和小分子疗法的当前文献进行系统审查.
- 开发一个基于证据的管理算法.
- 考虑患者的并发症,治疗反应,剂量调整和故障排除.
主要成果:
- 该审查综合了支持HS各种抗炎药物的证据.
- 建议采用算法方法来指导治疗决策.
- 该策略强调基于个体患者因素的个性化治疗.
结论:
- 高血压的有效管理需要一个全面的,基于证据的战略.
- 生物和小分子疗法为HS治疗提供了有前途的选择.
- 一种结构化,算法化的方法可以优化HS护理中的患者结果.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
88
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
88
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Drugs for Treatment of Ulcerative Colitis in IBD
116
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
116
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Inflammatory Bowel Disease V: Surgical Management
84
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
84
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
130
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
130


